SNT 2.56% 3.8¢ syntara limited

Agree with the primacy of results: delivering successful RCT's...

  1. 229 Posts.
    lightbulb Created with Sketch. 5

    Agree with the primacy of results: delivering successful RCT's and approvals etc. I think they have done a reasonable job so far in this regard, except perhaps for the bronchiectasis trial. I don't agree with Postman that the cash position and burn is a major factor, especially when bronchitol is close to market in both Aust/ Europe. The study results for CF were impressive and undeniable from a clinical viewpoint.
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
(20min delay)
Last
3.8¢
Change
-0.001(2.56%)
Mkt cap ! $45.37M
Open High Low Value Volume
3.9¢ 4.0¢ 3.7¢ $66.86K 1.754M

Buyers (Bids)

No. Vol. Price($)
1 82150 3.7¢
 

Sellers (Offers)

Price($) Vol. No.
3.8¢ 452640 1
View Market Depth
Last trade - 16.10pm 24/07/2024 (20 minute delay) ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.